Clinical trials: Asthma Patients
Asthma
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis.
- Trial name
- NCT06642961
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Asthma
A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.
The purpose of this study is to demonstrate that the CHF 1535 (fixed combination of Beclometasone Dipropionate (BDP) 100 µg / Formoterol Fumarate (FF) 6 µg) delivered via the NEXT Dry Powder Inhaler (DPI) does not show a greater…
- Trial name
- ADONE (NCT01191424)
- Testing
- CHF1535 NEXT DPI, BDP DPI and formoterol DPI
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
RISA Extension Study - Long Term Safety
The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter…
- Trial name
- NCT00401986
- Testing
- Bronchial thermoplasty with the Alair System
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 14 people
- Sponsor
- Boston Scientific Corporation
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests.
- Trial name
- NCT00296491
- Testing
- fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP)
- Where
- 121 sites in United States, Canada and 2 more
- Volunteers
- 725 people
- Sponsor
- GlaxoSmithKline
Allergy
Biological Standardization of Allergen Extracts of Pollens of Betula Pendula, Phleum Pratense and Mite Extract of Dermatophagoides Pteronyssinus
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of…
- Trial name
- NCT01147159
- Testing
- Extracts of allergens
- Where
- Switzerland
- Volunteers
- 68 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate
This study may last up to 36-38 weeks. Patients will visit the clinic 11 times. A blood sample will be taken at Visit 1 to look at subjects' genes. Breathing tests will be done during the study.
- Trial name
- NCT00102882
- Testing
- fluticasone propionate/salmeterol, salmeterol xinafoate
- Where
- 91 sites in United States, Kenya and 2 more
- Volunteers
- 547 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
This study will establish a clinical data and serum repository of anaphylaxis cases associated with Xolair administration and control patients who have received Xolair without associated anaphylaxis.
- Trial name
- X-PAND (NCT00813748)
- Testing
- Xolair
- Where
- 7 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.
Asthma
Dose Finding Study for QAW039 in Asthma
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy.
- Trial name
- NCT01437735
- Testing
- QAW039, Montelukast
- Where
- 206 sites in United States, Argentina and 20 more
- Volunteers
- 1,043 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
This study assessed the effect on asthma control of different dose levels and regimens of QGE031 in asthma patients that are inadequately controlled with inhaled steroid and beta-2 agonist medication. Safety was assessed also.
- Trial name
- NCT01716754
- Testing
- QGE031, Omalizumab
- Where
- 150 sites in United States, Argentina and 22 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately…
- Trial name
- NCT06829784
- Testing
- TQC2731 injection
- Where
- 101 sites in China
- Volunteers
- 660 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients with Asthma
- Trial name
- eMOFEE (NCT04869384)
- Testing
- Reminders and feedback to improve adherence, No reminders and feedback to improve adherence
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Orion Corporation, Orion Pharma
add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects.
- Trial name
- NCT04445038
- Testing
- 610
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
Asthma is a chronic inflammatory disorder of the airways with a variety of inflammatory processes contributing to the pathogenesis.
- Trial name
- NCT00486343
- Testing
- Zileuton CR
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Critical Therapeutics
Severe Uncontrolled Asthma
Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma
This pilot study will use novel technologies to collect information about the patient experience before and early after starting Fasenra (benralizumab) as standard of care for severe uncontrolled asthma in a real-world setting…
- Trial name
- TWINKLE (NCT04200326)
- Volunteers
- 5 people
- Sponsor
- AstraZeneca
Asthma, Allergies
Impact of Asthma Treatments on Daily Activities
The primary objective of this web-based, cross-sectional study is to assess and compare the ability to sleep, work or go to school, and to participate in leisure activities among subjects who are receiving Xolair treatment and…
- Trial name
- NCT00350376
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Ovation Research Group
Asthma
National Survey on Asthma
To evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms, according to the patient's level of asthma control.
- Trial name
- SYMPTOMES (NCT00770250)
- Where
- 905 sites in France
- Volunteers
- 1,704 people
- Sponsor
- AstraZeneca
Asthma, Bronchial
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
This is a multi-center, single-country, single-arm, prospective, disease study to collect real world data of patients with severe uncontrolled asthma in Germany.
- Trial name
- REACT-Asthma (NCT06299306)
- Where
- 6 sites in Germany
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
ASTHMA
A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes
TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow®…
- Trial name
- NCT05728749
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Chiesi SAS
Asthma
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver…
- Trial name
- GRECO (NCT02918071)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- AstraZeneca